Healthcare Providers and Services
Company Overview of Atherotech, Inc.
Atherotech, Inc. operates a diagnostic testing and disease management company. The company offers vertical auto profile test that measures the cholesterol content of all lipids, components, and subclasses. It provides testing services to physicians, hospitals, clinics, and other laboratories in the United States. The company was founded in 1996 and is headquartered in Birmingham, Alabama.
201 London Parkway
Birmingham, AL 35211
Founded in 1996
Key Executives for Atherotech, Inc.
Compensation as of Fiscal Year 2014.
Atherotech, Inc. Key Developments
Atherotech Diagnostics Lab Appoints Gerard Abate as Chief Clinical Officer
Sep 19 13
Atherotech Diagnostics Lab announced the addition of Gerard Abate, M.D., as the company's Chief Clinical Officer. Abate spent 14 years as a non-invasive clinical cardiologist and owner of Williamsburg Cardiology in Williamsburg, Va. He most recently served as Senior Medical Director for Thrombosis in Medical Affairs at Daiichi Sankyo.
Johns Hopkins, Atherotech Announce Strategic Research Collaboration to Fight Heart Disease
Sep 4 13
Atherotech Diagnostics Lab announced a strategic research collaboration with the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease. The partnership pairs Atherotech's Very Large Database of Lipids (VLDL) with Johns Hopkins' world-class cardiac research capabilities. The project's goal is to generate new knowledge through research, and translate that knowledge into clinical practice in the fight against cardiovascular disease. Using its proprietary VAP(R) Lipid Panel, Atherotech is the only company to consistently assess cholesterol-rich risk with directly measured LDL, HDL and subclasses; triglyceride-rich risk in remnant lipoproteins; and hereditary risk with Lp(a) -- all of which are represented in the total VLDL database of 8 million samples. The current research VLDL dataset has 1.4 million data points representing unique individuals, with more than 3 million data points anticipated for the next data harvest.
Atherotech Diagnostics Lab Adds Corgenix AspirinWorks Test for Aspirin Effect
Apr 2 13
Corgenix Medical Corporation has announced that Atherotech Diagnostics Lab will carry its AspirinWorks Test for determining aspirin effect. Under terms of the agreement, Corgenix' AspirinWorks product will be used to assess aspirin effect as part of Atherotech Diagnostic Lab's cardiometabolic testing products. AspirinWorks is the only U.S. FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect. The AspirinWorks Test identifies those individuals who have elevated thromboxane levels despite taking a daily aspirin dose, with studies showing up to 25% of individuals not seeing the expected beneficial effects of aspirin. The thromboxane metabolite 11dhTxB2 identified by AspirinWorks has been clinically validated through extensive research and numerous well-designed and well-powered clinical trials. The AspirinWorks 11dhTxB2 Test is FDA-cleared and used by thousands of physicians to test and guide treatment for hundreds of thousands of patients each year worldwide. Atherotech provides a full complement of more than 60 routine and specialty diagnostic tests, including its patented VAP Lipid Panel(R), to help physicians establish the most effective course of treatment from a single source.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries